Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
Mesenchymal Stromal (Stem) Cells
share announcement

Mesenchymal Stromal (Stem) Cells

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cell Biology and Pathology".

Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 9208

Special Issue Editor

Dr. Behnam Sadeghi

E-Mail Website
Guest Editor
Department of CLINTEC, Karolinska Institutet, TCR, KFC, NOVUM, Plan 6, Hälsovägen 7-9, 141 57 Huddinge, Sweden
Interests: therapeutic potential of human decidua stromal cells; hDSCs; pregnancy tolerance; DSCs/stromal cells; acute inflammatory diseases

Special Issue Information

Dear Colleagues,

Since the first description of mesenchymal stromal(/stem) cells (MSCs) by Friedenstein and colleagues in 1967, these cells have been used in more than 2000 registered clinical trials (Clinicaltrials.gov). MSCs have been used in a wide range of diseases, including musculoskeletal defects, disorders of the immune system (e.g., autoimmune diseases), and myocardial infarction. This Special Issue, on the subject of stromal cells intends to cover several aspects of stromal cells, from bench to bedside! Thus, several relevant subjects such as tissue sources, biology, in vitro assays, preclinical/clinical studies, regulatory/ethical aspects, and commercialization will be discussed in this Issue. Based on MSCs’ mechanisms of action, most clinical applications concentrate on inflammatory disorders and regenerative medicine. This has been extensively discussed, but gathering the latest findings in a collection still is required for scientists, physicians and investors for future planning.

We invite colleagues and authors to submit original research and review articles that are aligned with the scope of this Special Issue.

Dr. Behnam Sadeghi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • mesenchymal stromal cells (MSCs)
  • placenta derived stromal cells
  • cell therapy
  • regenerative medicine
  • clinical trials
  • preclinical studies
  • inflammatory diseases
  • immunomodulation
  • commercialization
  • regulatory issues

Published Papers (5 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

13 pages, 1316 KiB  
Article
Efficient Liposome Loading onto Surface of Mesenchymal Stem Cells via Electrostatic Interactions for Tumor-Targeted Drug Delivery
by Yusuke Kono, Renpei Kamino, Soma Hirabayashi, Takuya Kishimoto, Himi Kanbara, Saki Danjo, Mika Hosokawa and Ken-ichi Ogawara
Biomedicines 2023, 11(2), 558; https://doi.org/10.3390/biomedicines11020558 - 14 Feb 2023
Cited by 1 | Viewed by 1655
Abstract
Mesenchymal stem cells (MSCs) have a tumor-homing capacity; therefore, MSCs are a promising drug delivery carrier for cancer therapy. To maintain the viability and activity of MSCs, anti-cancer drugs are preferably loaded on the surface of MSCs, rather than directly introduced into MSCs. [...] Read more.
Mesenchymal stem cells (MSCs) have a tumor-homing capacity; therefore, MSCs are a promising drug delivery carrier for cancer therapy. To maintain the viability and activity of MSCs, anti-cancer drugs are preferably loaded on the surface of MSCs, rather than directly introduced into MSCs. In this study, we attempted to load liposomes on the surface of MSCs by using the magnetic anionic liposome/atelocollagen complexes that we previously developed and assessed the characters of liposome-loaded MSCs as drug carriers. We observed that large-sized magnetic anionic liposome/atelocollagen complexes were abundantly associated with MSCs via electrostatic interactions under a magnetic field, and its cellular internalization was lower than that of the small-sized complexes. Moreover, the complexes with higher atelocollagen concentrations showed lower cellular internalization than the complexes with lower atelocollagen concentrations. Based on these results, we succeeded in the efficient loading of liposomes on the surface of MSCs by using large-sized magnetic anionic liposomes complexed with a high concentration of atelocollagen. The constructed liposome-loaded MSCs showed a comparable proliferation rate and differentiation potential to non-loaded MSCs. Furthermore, the liposome-loaded MSCs efficiently adhered to vascular endothelial cells and migrated toward the conditioned medium from cancer cells in vitro and solid tumor tissue in vivo. These findings suggest that liposome-loaded MSCs could serve as an efficient cell-based drug carrier for tumor-targeted delivery. Full article
(This article belongs to the Special Issue Mesenchymal Stromal (Stem) Cells)
►▼ Show Figures

Graphical abstract

11 pages, 5344 KiB  
Article
Infusion of Some but Not All Types of Human Perinatal Stromal Cells Prevent Organ Fibrosis in a Humanized Graft versus Host Disease Murine Model
by Ramon E. Coronado, Elena Stavenschi Toth, Maria Somaraki-Cormier, Naveen Krishnegowda and Shatha Dallo
Biomedicines 2023, 11(2), 415; https://doi.org/10.3390/biomedicines11020415 - 31 Jan 2023
Viewed by 1306
Abstract
Allogeneic transplant rejection represents a medical complication that leads to high morbidity and mortality rates. There are no treatments to effectively prevent fibrosis; however, there is great interest in evaluating the use of perinatal mesenchymal stromal cells (MSCs) and other MSCs to prevent [...] Read more.
Allogeneic transplant rejection represents a medical complication that leads to high morbidity and mortality rates. There are no treatments to effectively prevent fibrosis; however, there is great interest in evaluating the use of perinatal mesenchymal stromal cells (MSCs) and other MSCs to prevent fibrosis associated with chronic rejection. In this study, we isolated human perinatal stromal cells (PSCs) from amnion (AM-PSC), placental villi (PV-PSC), and umbilical cord (UC-PSC) tissues, demonstrating the phenotypic characteristics of MSCs as well as a >70% expression of the immunomodulatory markers CD273 and CD210. The administration of a single dose (250,000 cells) of each type of PSC in a humanized graft versus host disease (hGvHD) NSG® murine model delayed the progression of the disease as displayed by weight loss and GvHD scores ranging at various levels without affecting the hCD3+ population. However, only PV-PSCs demonstrated an increased survival rate of 50% at the end of the study. Furthermore, a histopathological evaluation showed that only PV-PSC cells could reduce human CD45+ cell infiltration and the fibrosis of the lungs and liver. These findings indicate that not all PSCs have similar therapeutic potential, and that PV-PSC as a cell therapeutic may have an advantage for targeting fibrosis related to allograft rejection. Full article
(This article belongs to the Special Issue Mesenchymal Stromal (Stem) Cells)
►▼ Show Figures

Figure 1

14 pages, 5844 KiB  
Article
Urinary Bladder Patch Made with Decellularized Vein Scaffold Seeded with Adipose-Derived Mesenchymal Stem Cells: Model in Rabbits
by Tadeu Ravazi Piovesana, Lenize da Silva Rodrigues, Ana Livia de Carvalho Bovolato, Diego Noé Rodríguez-Sánchez, Jaqueline Carvalho Rinaldi, Nilton José Santos, Julia Calvi Mori, Pedro Luiz Toledo de Arruda Lourenção, Lynn Birch and Matheus Bertanha
Biomedicines 2022, 10(11), 2814; https://doi.org/10.3390/biomedicines10112814 - 04 Nov 2022
Cited by 1 | Viewed by 1483
Abstract
Background: To evaluate tissue regeneration of the urinary bladder after the implantation of a decellularized vein sown with autologous adipose-derived mesenchymal stem cells (ASC) on luminal surfaces. Methods: New Zealand rabbits (n = 10) were distributed in two groups: Group Bioscaffold alone [...] Read more.
Background: To evaluate tissue regeneration of the urinary bladder after the implantation of a decellularized vein sown with autologous adipose-derived mesenchymal stem cells (ASC) on luminal surfaces. Methods: New Zealand rabbits (n = 10) were distributed in two groups: Group Bioscaffold alone (G1)-decellularized vena cava (1 cm2) was implanted, and Group Bioscaffold plus ACSs (G2)-decellularized vena cava (1 cm2) containing ASCs were implanted. ASCs were expanded, characterized, and maintained for one week in culture with a decellularized vein scaffold. The implants were performed under general anesthesia using a continuous suture pattern. Afterward, 21 d (day) specimens were collected and analyzed by hematoxylin and eosin (HE) histology and scanning electron microscopy (SEM). Results: The integrity of the urinary bladder was maintained in both groups. A superior regenerative process was observed in the G2 group, compared to the G1 group. We observed a greater urothelial epithelialization and maturity of the mucosa and submucosa fibroblasts. Furthermore, SEM demonstrated a notable amount of urothelial villus in the G2 group. Conclusion: Decellularized vena cava scaffolds were able to maintain the integrity of the urinary bladder in the proposed model. In addition, ASCs accelerated the regenerative process development, observed primarily by the new urothelial epithelization and the maturity of mucosa and submucosa fibroblasts. Full article
(This article belongs to the Special Issue Mesenchymal Stromal (Stem) Cells)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

20 pages, 381 KiB  
Review
Multilineage-Differentiating Stress-Enduring Cells (Muse Cells): The Future of Human and Veterinary Regenerative Medicine
by María Gemma Velasco, Katy Satué, Deborah Chicharro, Emma Martins, Marta Torres-Torrillas, Pau Peláez, Laura Miguel-Pastor, Ayla Del Romero, Elena Damiá, Belén Cuervo, José María Carrillo, Ramón Cugat, Joaquín Jesús Sopena and Mónica Rubio
Biomedicines 2023, 11(2), 636; https://doi.org/10.3390/biomedicines11020636 - 20 Feb 2023
Cited by 1 | Viewed by 2390
Abstract
In recent years, several studies have been conducted on Muse cells mainly due to their pluripotency, high tolerance to stress, self-renewal capacity, ability to repair DNA damage and not being tumoral. Additionally, since these stem cells can be isolated from different tissues in [...] Read more.
In recent years, several studies have been conducted on Muse cells mainly due to their pluripotency, high tolerance to stress, self-renewal capacity, ability to repair DNA damage and not being tumoral. Additionally, since these stem cells can be isolated from different tissues in the adult organism, obtaining them is not considered an ethical problem, providing an advantage over embryonic stem cells. Regarding their therapeutic potential, few studies have reported clinical applications in the treatment of different diseases, such as aortic aneurysm and chondral injuries in the mouse or acute myocardial infarction in the swine, rabbit, sheep and in humans. This review aims to describe the characterization of Muse cells, show their biological characteristics, explain the differences between Muse cells and mesenchymal stem cells, and present their contribution to the treatment of some diseases. Full article
(This article belongs to the Special Issue Mesenchymal Stromal (Stem) Cells)

Other

Jump to: Research, Review

7 pages, 446 KiB  
Case Report
Mesenchymal Stromal Cell Therapy Reverses Detrusor Hypoactivity in a Chronic Kidney Patient
by Henrique Rodrigues Scherer Coelho, Silvia Cordeiro das Neves, Jovino Nogueira da Silva Menezes, Andréia Conceição Milan Brochado Antoniolli-Silva and Rodrigo Juliano Oliveira
Biomedicines 2023, 11(1), 218; https://doi.org/10.3390/biomedicines11010218 - 14 Jan 2023
Cited by 1 | Viewed by 1362
Abstract
Detrusor hypoactivity (DH) is characterized by low detrusor pressure or a short contraction associated with low urinary flow. This condition can progress to chronic renal failure (CRF) and result in the need for dialysis. The present case report demonstrates that a patient diagnosed [...] Read more.
Detrusor hypoactivity (DH) is characterized by low detrusor pressure or a short contraction associated with low urinary flow. This condition can progress to chronic renal failure (CRF) and result in the need for dialysis. The present case report demonstrates that a patient diagnosed with DH and CRF who received two transplants with 2 × 106 autologous mesenchymal stromal cells at an interval of 30 days recovered the contractile strength of the bladder and normalized his renal function. The patient had a score of 19 on the ICIQ-SF before cell therapy, and that score was reduced to 1 after transplantation. These results demonstrate that there was an improvement in his voiding function, urinary stream and urine volume as evaluated by urofluxometry. In addition, a urodynamic study carried out after treatment showed an increase in the maximum flow from 2 mL/s to 23 mL/s, the detrusor pressure in the maximum flow from 21 cm H2O to 46 cm H2O and a BCI that went from 31 to 161, characterizing good detrusor contraction. Thus, in the present case, the transplantation of autologous mesenchymal stromal cells proved to be a viable therapeutic option to allow the patient to recover the contractile strength of the bladder, and reversed the CRF. Full article
(This article belongs to the Special Issue Mesenchymal Stromal (Stem) Cells)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-5
Back to TopTop